Physician profile
Robert J Roddy
NPI 1831197649
$418.85
in general payments reported to CMS, 2019-2025
13 companies · $13.47 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.52 · 2021: $33.68 · 2022: $156 · 2023: $105 · 2024: $57.61 · 2025: $13.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.94 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $92.14 | 2022-2023 | Qelbree |
| Almatica Pharma LLC | $70.98 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Neurocrine Biosciences, INC. | $49.30 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.49 | 2022-2023 | |
| Abbvie INC. | $30.34 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Shire North American Group INC | $25.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.81 | 2023 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $15.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.95 | 2023 | Abilify Maintena, Rexulti |
| Idorsia Pharmaceuticals US INC | $12.08 | 2022 | |
| Alkermes, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.